Cytoplasmic expression of survivin is an independent predictor of poor prognosis in patients with salivary gland cancer

Histopathology

Volumn 57, Issue 5, 2010, Pages 699-706

  Stenner, Markus ^a   Weinell, Antje ^a   Ponert, Tobias ^a   Hardt, Aline ^a   Hahn, Moritz ^a   Preuss, Simon F ^a   Guntinas Lichius, Orlando ^b   Klussmann, Jens Peter ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Adenocarcinoma; Immunohistochemistry; Muco epidermoid carcinoma; Prognosis; Salivary gland cancer; Survivin

Indexed keywords

SURVIVIN;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PAROTID GLAND CANCER; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALIVARY GLAND ADENOCARCINOMA; SALIVARY GLAND CARCINOMA; SCHOOL CHILD; SURVIVAL RATE;

ADULT; CARCINOMA, SQUAMOUS CELL; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PROGNOSIS; SALIVARY GLAND NEOPLASMS; SURVIVAL RATE;

EID: 78449274426     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03693.x     Document Type: Article

References (29)

1. Vander Poorten VL. Salivary gland carcinoma - stepping up the prognostic ladder. Amsterdam, the Netherlands: University of Amsterdam, 2002; 222.
2. Barnes L, Eveson JW, Reichart P et al. eds. Tumours of the salivary gland. In Pathology and genetics. Head and neck tumours. World Health Organization Classification of Tumours. Lyon, France: IARC Press, 2005; 209-281.
3. Chandana SR, Conley BA. Salivary gland cancers: current treatments, molecular characteristics and new therapies. Expert Rev. Anticancer Ther. 2008; 8; 645-652.
4. Rapidis AD, Givalos N, Gakiopoulou H et al. Mucoepidermoid carcinoma of the salivary glands. Review of the literature and clinicopathological analysis of 18 patients. Oral Oncol. 2007; 43; 130-136.
5. Speight PM, Barrett AW. Salivary gland tumours. Oral Dis. 2002; 8; 229-240.
6. Poorten VV, Hart A, Vauterin T et al. Prognostic index for patients with parotid carcinoma: international external validation in a Belgian-German database. Cancer 2009; 115; 540-550.
7. Leivo I. Insights into a complex group of neoplastic disease: advances in histopathologic classification and molecular pathology of salivary gland cancer. Acta Oncol. 2006; 45; 662-668.
8. Luukkaa H, Klemi P, Leivo I, Vahlberg T, Grenman R. Prognostic significance of Ki-67 and p53 as tumour markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol. 2006; 45; 669-675.
9. Jaskoll T, Chen H, Min Zhou Y, Wu D, Melnick M. Developmental expression of survivin during embryonic submandibular salivary gland development. BMC Dev. Biol. 2001; 1; 5.
10. Schmitz M, Diestelkoetter P, Weigle B et al. Generation of survivin-specific CD8CT effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000; 60; 4845-4849.
11. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med. Electron Microsc. 2001; 34; 207-212.
12. Qi H, Wang KM, Liang YQ, Yang LL. [Expression and clinic pathological significance of survivin mRNA and protein in salivary gland tumours]. Shanghai Kou Qiang Yi Xue 2007; 16; 18-23.
13. Preuss SF, Weinell A, Molitor M et al. Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br. J. Cancer 2008; 98; 627-632.
14. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008; 8; 61-70.
15. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22; 8581-8589.
16. Li F. Survivin study: what is the next wave? J. Cell. Physiol. 2003; 197; 8-29.
17. Nikitakis NG, Scheper MA, Papanikolaou VS, Sauk JJ. The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2009; 107; 826-836.
18. Nikitakis NG, Scheper MA, Papanikolaou VS, Sklavounou A, Sauk JJ. Immunohistochemical expression of the oncogenic molecules active Stat3 and survivin in benign and malignant salivary gland tumours. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2009; 107; 837-843.
19. Lo Muzio L, Pannone G, Staibano S et al. Survivin expression in oral squamous cell carcinoma. Br. J. Cancer 2003; 12; 2244-2248.
20. Lu CS, Kashima K, Daa T, Yokoyama S, Yanagisawa S, Nakayama I. Immunohistochemical study of the distribution of endogenous biotin and biotin-binding enzymes in ductal structures of salivary gland tumours. J. Oral Pathol. Med. 2000; 29; 445-451.
21. Giefing M, Wierzbicka M, Rydzanicz M, Cegla R, Kujawski M, Szyfter K. Chromosomal gains and losses indicate oncogene and tumour suppressor gene candidates in salivary gland tumours. Neoplasma 2008; 55; 55-60.
22. Boahene DK, Olsen KD, Lewis JE, Pinheiro AD, Pankratz VS, Bagniewski SM. Mucoepidermoid carcinoma of the parotid gland: the Mayo clinic experience. Arch. Otolaryngol. Head Neck Surg. 2004; 130; 849-856.
23. Pires FR, De Almeida OP, De Araújo VC, Kowalski LP. Prognostic factors in head and neck mucoepidermoid carcinoma. Arch. Otolaryngol. Head Neck Surg. 2004; 130; 174-180.
24. Wahlberg P, Anderson H, Biörklund A, Möller T, Perfekt R. Carcinoma of the parotid and submandibular glands - a study of survival in 2465 patients. Oral Oncol. 2002; 38; 706-713.
25. Lee J, Kang WK, Park JO et al. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS 2009; 117; 598-606.
26. Altieri DC. New wirings in the survivin networks. Oncogene 2008; 27; 6276-6284.
27. Münger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 2002; 89; 213-228.
28. Hauser U, Balz V, Carey TE et al. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 2002; 24; 868-873.
29. Altieri DC. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol. Cancer Ther. 2006; 5; 478-482.